Triapine

Catalog No.S7470 Synonyms: 3-AP

For research use only.

Triapine (3-AP) is a potent ribonucleotide reductase (RNR) inhibitor with broad spectrum antitumor activity by inhibiting DNA synthesis. Phase 2.

Triapine Chemical Structure

CAS No. 200933-27-3

Selleck's Triapine has been cited by 11 Publications

1 Customer Review

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Other DNA/RNA Synthesis Products

Biological Activity

Description Triapine (3-AP) is a potent ribonucleotide reductase (RNR) inhibitor with broad spectrum antitumor activity by inhibiting DNA synthesis. Phase 2.
Targets
Ribonucleotide reductase [1]
In vitro

Triapine potently inhibits the activity of ribonucleotide reductase in both wild-type KB and HU-resistant KB nasopharyngeal carcinoma cells. Triapine shows broad spectrum antitumor activity by inhibiting DNA synthesis in a series of cancer cell lines. [1] In vitro, Triapine blocks ischemic neurotoxicity and hypoxic toxicity with EC50 of 0.35 μM and 0.75 μM, respectively. Triapine also shows its neuroprotective activity by suppressing cell death induced by neurotoxic agents, including staurosporine, veratridine and glutamate. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-MC NHfFVZNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M1racmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1OSyClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5|Md88US=> M3u1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUSyNFQ3Lz5zN{G0NlA1PjxxYU6=
SK-N-MC MmTWRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M2XnTlczKGi{cx?= NXnBdHdlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU2FIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4zPs7:TR?= NVzlWIx4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NFI3ODNpPkG3OlAzPjB|PD;hQi=>
SK-N-MC NHXq[mJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NYHUeotNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU2FIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkW0{txO NHm0WmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m2N|M4Oid-MUe5OlM{PzJ:L3G+
BT-37 MWfxTHRUKGG|c3H5 M4rz[pFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= NX\SU2w{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUixOVk6OjJpPkG4NVU6QTJ{PD;hQi=>
KB-3-1 Ml25R5l1d3SxeHnjbZR6KGG|c3H5 NWnvO4JXPzJiaILz NGLoO|lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRNWeyLX7l[4F1cX[nIFvCMVMuOSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuOO69VQ>? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTN7N{OyNkc,OTl|OUezNlI9N2F-
KB-3-1 MYnDfZRwfG:6aXPpeJkh[XO|YYm= MX:3NkBpenN? NX3OepR6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWC2pcD3u[YdifGm4ZTDLRk0{NTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlQyOjV2zszN NEm3e489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO5O|MzOid-MUmzPVc{OjJ:L3G+
KBV1 NYW3VmJ[S3m2b4TvfIlkcXS7IHHzd4F6 NV7kUlExPzJiaILz MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdtgWOxcILveIVqdi2neIDy[ZN{cW6pIFvCWlEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13Lki4PFQ1|ryP M4qyPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{m3N|IzLz5zOUO5O|MzOjxxYU6=
KBV1 NUDDNJF5S3m2b4TvfIlkcXS7IHHzd4F6 NXnCRVVIPzJiaILz MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdtgWOxcILveIVqdi2neIDy[ZN{cW6pIFvCWlEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13LkpOwG0> NIKzemw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO5O|MzOid-MUmzPVc{OjJ:L3G+
SK-N-MC M1;ZbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MmHaO|IhcHK| M2O5NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1OSyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNlbPxE1? NHu2fXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[wNVU4Pyd-MUm2NFE2Pzd:L3G+
HCT116 NGrU[GtF[XKtIHP5eI91d3irY3n0fUBie3OjeR?= NGDjRZc6PiCqcoO= NUHJPHJJTGG{azDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGVicEWzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT6yNlbPxE1? M{fi[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFM4Lz5{NEmwNFg{PzxxYU6=
HCT116 NFfNXZlRcG:2b3P5eI91d3irY3n0fUBie3OjeR?= MmPDNlQhcHK| MnfNVIhwfG:leYTveI95cWOrdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUheDV|IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIZwdGyxd3XkJIJ6KGyrZ3j0JIlzemGmaXH0bY9vKG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBOXFNiYYPzZZkhcW5icILld4Vv[2Vib3[gRWxCKGGwZDDG[WNtOw>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizO{c,OjR7MEC4N|c9N2F-
HCT116 MXnGeY5kfGmxbjDhd5NigQ>? NWHOZW9oPCC3TR?= MoHiNlQhcHK| MVvJcoR2[3Srb36gc4YhWk:VIHflcoVz[XSrb36gbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIIC1N{BifCB2IIXNJIFnfGW{IEK0JIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eR?= M1HybFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFM4Lz5{NEmwNFg{PzxxYU6=
NB-EBc1 M3jZV5FJXFNiYYPzZZk> MojUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= Mn7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|M{[2PFQoRjJ5M{O2Olg1RC:jPh?=
OHS-50 M{LYTpFJXFNiYYPzZZk> NIHXNXNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz NWfkXYVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezN|Y3QDRpPkK3N|M3Pjh2PD;hQi=>
KB-3-1 MYfDfZRwfG:6aXPpeJkh[XO|YYm= MXq3NkBpenN? Mle0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2IuOy1zIHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2zMlHPxE1? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN|Nk[4OEc,Ojd|M{[2PFQ9N2F-
KBC1 M37w[mN6fG:2b4jpZ4l1gSCjc4PhfS=> NGD1bow4OiCqcoO= NH[4cXZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSkNzIHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME24MlnPxE1? NWr4[4NkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezN|Y3QDRpPkK3N|M3Pjh2PD;hQi=>
SW480 MVjGeY5kfGmxbjDhd5NigQ>? MonuNk42KHWP MVe0PEBpenN? NGTJb2FKdmS3Y4Tpc44hd2ZibX;ydIhwdG:paXPhcEBkcGGwZ3XzJIlvKGi3bXHuJHNYPDhyIHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBu[XO|aY\lJINmdGxiZnzheJRmdmmwZzDheEAzNjVidV2gbY5kfWKjdHXkJIZweiB2ODDodpMh[nlicHjhd4Uh[2:wdILhd5QhdWmlcn;zZ49xgQ>? NIfESZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{OzOlY5PCd-MkezN|Y3QDR:L3G+
HL60 MUjGeY5kfGmxbjDhd5NigQ>? M{j4VFEh[W6mIEWgeW0> NXuxeJRiOzBibXnudy=> M3r4UWlv\HWldHnvckBw\iCrboTyZYNmdGy3bHHyJHJQWyCpZX7ldoF1cW:wIHnuJIh2dWGwIFjMOlAh[2WubIOgZZQhOSCjbnSgOUB2VSCrbjDwdoV{\W6lZTDv[kBEfUOuMjDpcoN2[mG2ZXSg[o9zKDNyIH3pcpMh[nliRFPGMWRCKHO2YXnubY5oKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfS=> Mn;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|M{[2PFQoRjJ5M{O2Olg1RC:jPh?=
L1210 MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUDRWJdIT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhVDF{MUCgZ4VtdHNiYomgUXRUKGG|c3H5MEBKSzVyPUGuN:69VQ>? NV;UN2xPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NFQ4QDJpPkOwPVA1Pzh{PD;hQi=>
SJ-GBM2 Mor0dWhVWyCjc4PhfS=> NGLvfldyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF4MUSyOVcoRjNzNkG0NlU4RC:jPh?=
WPMY-1 M3\PVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MWO3NkBpenN? NX2zS3pQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDXVG1[NTFiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxicILvcIln\XKjdHnvckBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;ND65Ou69VQ>? MkjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF4MUSyOVcoRjNzNkG0NlU4RC:jPh?=
GES-1 NVfneoZCSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MX23NkBpenN? NH7jUFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfFV{0yKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTVwNt88US=> MmfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF4MUSyOVcoRjNzNkG0NlU4RC:jPh?=
HEK293 NWDjXGd1S3m2b4TvfIlkcXS7IHHzd4F6 NWLYV2tUS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJEhEVy2DRFS6UWFgODB5KUugR2M2OCCkeTDj[YxtKH[rYXLpcIl1gSCjc4PhfUBqdiCGTVXNJEgyOCViRlLTLUBu\WSrYTD1d4lv\yCWQzDwcIF1\XNuIHL5JHJme2G8dYLpckBHMDV4MD:1PVAqNCCFQ{WwQVIvQDJ5zszN MoTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlMyPjF4Lze+R4hGVUKOPD;hQi=>
GES-1 M{Ph[mN6fG:2b4jpZ4l1gSCjc4PhfS=> M2fmPVczKGi{cx?= M2Lke2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdGWy1zIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU41|ryP NFPaTo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOzF4MU[vK|5EcEWPQly8M4E,
MGC803 M2XDTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M334WFczKGi{cx?= M{LnO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVfDPFA{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT62PO69VQ>? NXvrUIp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjNzNkG2M{c,S2iHTVLMQE9iRg>?
MCF7 NELOTWNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXe3NkBpenN? M2DI[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTF6Lki1{txO MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyN|E3OTZxJ{7DbGVOSkx:L3G+
SMMC7721 M1rhN2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NIDEcpA4OiCqcoO= NXrPfmRoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTUW1EPzd{MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQzNjhzzszN M4LSWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI{OTZzNj:nQmNpTU2ETEyvZV4>
Assay
Methods Test Index PMID
Western blot p-Chk1 / Chk1 / p-CDK1/2 / CDK1/2 / p-H1 24413181
Growth inhibition assay Cell viability 31118677
In vivo In mice bearing the L1210 leukemia, Triapine (1.25 to 20 mg/kg) is curative for some mice without lethal toxicity. Triapine also inhibits the growth of solid tumors in mice M109 lung carcinoma and human A2780 ovarian carcinoma xenografts. In addition, combination of Triapine with various classes of agents that damage DNA results in synergistic inhibition of the L1210 leukemia. [1] In a rat model of transient ischemia, Triapine reduces infarct volume by 59% when administered i.c.v. (50 μ per rat) and by 35% when administered i.v. (1 mg/kg). [2]

Protocol (from reference)

Kinase Assay:

[1]

  • Ribonucleotide reductase assay:

    CDP reductase is assayed using Dowex 1-borate ion-exchange chromatography. The assay mixture contains 0.02 μCi of [14C]CDP (52.9 mCi/mmol), 3 mM dithiothreitol, 6 mM MgCl2, 30 mM HEPES, 5 mM ATP, 0.15 mM unlabeled CDP, and 10 μL of cellular extract in a final volume of 0.02 mL. The incubation time for the reaction is 60 min, during which time the reaction is linear.

Cell Research:

[1]

  • Cell lines: Wild-type KB and HU-resistant KB nasopharyngeal carcinoma cells.
  • Concentrations: ~10 μM
  • Incubation Time: A period of 3 generations
  • Method:

    Cells are plated at a density of 104 cells/mL per well in 24-well plates. Drugs are added to cells and incubations are continued for a period of 3 generations (untreated control cells), followed by assessment of cell growth by the methylene blue assay.

Animal Research:

[1]

  • Animal Models: BALB/cBA/2 (CD2F1) mice with the L1210 leukemia and the M109 lung carcinoma, athymic nu/nu mice with the human A2780 ovarian carcinoma xenograft.
  • Dosages: ~24 mg/kg
  • Administration: i.p. or i.v.

Solubility (25°C)

In vitro

DMSO 20 mg/mL
(102.43 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.

1.25mg/mL

Chemical Information

Molecular Weight 195.24
Formula

C7H9N5S

CAS No. 200933-27-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=C(N=C1)C=NNC(=S)N)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04234568 Recruiting Drug: Lutetium Lu 177 Dotatate|Drug: Triapine Digestive System Neuroendocrine Tumor|Metastatic Well Differentiated Neuroendocrine Neoplasm National Cancer Institute (NCI) June 29 2020 Phase 1
NCT00293345 Completed Drug: gemcitabine hydrochloride|Drug: triapine Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) June 2006 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Triapine | Triapine supplier | purchase Triapine | Triapine cost | Triapine manufacturer | order Triapine | Triapine distributor